PF 06281355

Key Product Details

Product Description

PF 06281355 is a selective myeloperoxidase (MPO) inhibitor (IC₅₀ = 1.5 μM in LPS-stimulated human whole blood). Selective for MPO over a panel of 50 receptors, enzymes, ion channels and transporters, including thyroid peroxidase. Inhibits MPO activity in peritoneal lavage and plasma in a murine peritonitis model. Also reduces lung edema in a murine pulmonary immune complex vasculitis model. Orally bioavailable.

Licensing Information

Sold for research purposes under agreement from Pfizer Inc

Product Specifications for PF 06281355

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for PF 06281355

The following data is based on the product molecular weight 321.35.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
0.2 mM	15.56 mL	77.80 mL	155.59 mL
1 mM	3.11 mL	15.56 mL	31.12 mL
2 mM	1.56 mL	7.78 mL	15.56 mL
10 mM	0.31 mL	1.56 mL	3.11 mL

Calculators

Background References

References are publications that support the biological activity of the product.

• Ruggeri Discovery of 2-(6-(5-chloro-2-methoxyphenyl)-4-oxo-2-thioxo-3,4-dihydropyrimidin-1(2H)-yl)acetamide (PF-06282999): A highly selective mechanism-based myeloperoxidase inhibitor for the treatment of cardiovascular diseases. J.Med.Chem. 2015 PMID: 26509551
• Zheng PF-1355, a mechanism-based myeloperoxidase inhibitor, prevents immune complex vasculitis and anti-glomerular basement membrane glomerulonephritis. J.Pharmacol.Exp.Ther. 2015 PMID: 25698787

Product Documents for PF 06281355